Jisandai (Bingtonsha) Medical Insurance Reimbursement Price and Purchasing Guide

Epclusa (Epclusa), an oral antiviral drug developed by Gilead Sciences, is designed to treat chronic hepatitis C virus (HCV) infection of all genotypes. Its core ingredients include Sofosbuvir (Sofosbuvir) and Velpatasvir (Velpatasvir), which act as nucleotide polymerase inhibitors and NS5A inhibitors respectively. They work synergistically to effectively block the replication and spread of hepatitis C virus.

At present, Jisandai (Bingtonsha) has been launched in the Chinese market and has been successfully included in the medical insurance directory, providing patients with a convenient channel to purchase domestically. Its price is relatively affordable, about more than 3,000 yuan. However, specific prices and health insurance reimbursement details may vary by region, so patients are advised to consult their local hospital or pharmacy for accurate information before purchasing. Compared with the domestic market, generic drugs produced in India and Bangladesh are cheaper, costing only a few hundred yuan, and their drug ingredients are basically the same as the domestic versions.

Bingtonsa is excellent in treating hepatitis C and is suitable for patients with all six genotypes, regardless of whether they have cirrhosis or not. For patients with decompensated cirrhosis, the combined use of Bingtonsa and Ribavirin can further improve the therapeutic effect. Taking one tablet daily for a 12-week treatment cycle can enable the vast majority of patients to achieve a sustained virological response (SVR12) treatment effect.

Clinical trial data further confirms the therapeutic effect of Jisandai (Bingtonsha). Its cure rate for HCV patients of various genotypes exceeds 95%. Although some minor side effects, such as headache, fatigue and nausea, may occur during use, patients with severe liver damage should have their liver function status closely monitored during treatment.

During the use of Gisanda (Bingtonsa), patients need to be careful not to take proton pump inhibitors that may interfere with drug absorption at the same time. In addition, regular monitoring of viral load and liver function is also an important part of the treatment process. It is important to note that Jisandai (Bingtonsha) is not suitable for pregnant and lactating women. Before starting treatment, patients should inform their doctor in detail about all medications they are taking and potential health problems to ensure the safety and effectiveness of the treatment.